

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-6. (cancelled)

7. (currently amended) A fusion ~~polypeptide~~ protein specifically inhibiting the translation of a target polynucleotide of interest, comprising: SEQ ID NO 5.

~~a peptide inhibitor of the translation of proteins, said peptide inhibitor having a length up to 250 amino acids and comprising an amino acid sequence possessing at least 85% identity with the amino acid sequence SEQ ID N° 1; and~~

~~an RNA binding protein consisting of MS2CP,~~

~~wherein said peptide inhibitor is fused with said RNA binding protein, said peptide inhibitor fused with said RNA binding protein is one of SEQ ID N° 5 and SEQ ID N° 6.~~

8-36. (cancelled)

37. (previously presented) A pharmaceutical composition comprising a fusion polypeptide according to claim 7.

38-40. (cancelled)

41. (currently amended) A fusion ~~polypeptide~~
protein specifically inhibiting the translation of a target
polynucleotide of interest, consisting of SEQ ID NO 5.~~of one~~
~~of SEQ ID N° 5 and SEQ ID N° 6.~~

42. (previously presented) A pharmaceutical composition
comprising a fusion polypeptide according to claim 41.